X0306 4 2021-02-03 0 0001438533 Travere Therapeutics, Inc. TVTX 0001579649 Rosenberg Noah L. C/O RETROPHIN, INC. 3611 VALLEY CENTRE DRIVE, SUITE 300 SAN DIEGO CA 92130 0 1 0 0 Chief Medical Officer Common Stock 2021-02-03 4 A 0 4500 0.00 A 48594 D (1) On January 31, 2020, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 9,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones. On February 3, 2021, a portion of the PRSUs vested upon the Issuer's confirmation of the satisfaction of a performance criterion related to the interim data read-out from the DUPLEX study. /s/ Elizabeth E. Reed, Attorney-in-Fact 2021-02-05